JPH10139654A - Composition for external skin use - Google Patents

Composition for external skin use

Info

Publication number
JPH10139654A
JPH10139654A JP8312965A JP31296596A JPH10139654A JP H10139654 A JPH10139654 A JP H10139654A JP 8312965 A JP8312965 A JP 8312965A JP 31296596 A JP31296596 A JP 31296596A JP H10139654 A JPH10139654 A JP H10139654A
Authority
JP
Japan
Prior art keywords
component
skin
extract
composition
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP8312965A
Other languages
Japanese (ja)
Inventor
Yoshimasa Tanaka
良昌 田中
Hisao Shimogaki
久夫 霜垣
Shinichi Watanabe
真一 渡辺
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lion Corp
Original Assignee
Lion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lion Corp filed Critical Lion Corp
Priority to JP8312965A priority Critical patent/JPH10139654A/en
Publication of JPH10139654A publication Critical patent/JPH10139654A/en
Pending legal-status Critical Current

Links

Landscapes

  • Cosmetics (AREA)

Abstract

PROBLEM TO BE SOLVED: To prepare a composition for external skin use excellent in skin beautifying and whitening actions, safety and stability without causing skin rash by including a substance capable of inhibiting or suppressing activities of tyrosinases, a specific extract and a flavonoid extract from Glycyrrhizae Radix therein. SOLUTION: This composition for external skin use comprises (A) preferably 0.05-10wt.% substance capable of inhibiting or suppressing activities of tyrosinases such as an ellagic acid-based compound, (B preferably 0.1-10wt.% extract selected from soybean (meal) or a fermentation product obtained by using the soybean (meal) as a raw material and (C) preferably 0.01-10wt.% flavonoid extract from Glycyrrhizae Radix or its ingredient.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は、優れた皮膚美白作
用を有する皮膚外用組成物に関する。
TECHNICAL FIELD The present invention relates to a composition for external use on skin having an excellent skin whitening effect.

【0002】[0002]

【従来の技術】皮膚のシミやソバカスなどの色素沈着の
発生機序については不明な点が多いが、一般にはホルモ
ン異常や紫外線による刺激が原因となって、メラニン色
素が過剰に生成し、皮膚内に異常沈着するものと考えら
れている。このような色素沈着を予防又は改善する目的
で、従来から、過酸化水素、過酸化亜鉛、過酸化マグネ
シウムなどの過酸化物、あるいはアスコルビン酸、グル
タチオン、コロイドイオウ、各種天然物などを有効成分
とする美白化粧料の使用が試みられてきた。しかしなが
ら、これらの有効成分の多くは、安全性や安定性が十分
でなかったり、あるいは匂いなどに問題がある上、その
効果についても、必ずしも十分なものとはいえなかっ
た。一方、米国などにおいては、ハイドロキノンが皮膚
脱色剤として使用されているが、このハイドロキノンは
刺激性やアレルギー性を有し、安全性の面から、有効成
分として化粧料に配合するには問題がある。従って、こ
のような欠点を伴わずに、皮膚美白効果を奏する化粧料
を開発するための種々の研究が行われてきた.
2. Description of the Related Art There are many unclear points about the mechanism of pigmentation such as skin spots and freckles, but in general, abnormalities of hormones and stimulation by ultraviolet rays cause excessive production of melanin pigment, It is believed to be abnormally deposited within. For the purpose of preventing or improving such pigmentation, conventionally, hydrogen peroxide, zinc peroxide, peroxides such as magnesium peroxide, or ascorbic acid, glutathione, colloidal sulfur, various natural products and the like as an active ingredient. Attempts have been made to use whitening cosmetics. However, many of these active ingredients have insufficient safety and stability, or have problems with odor and the like, and their effects are not necessarily sufficient. On the other hand, in the United States and the like, hydroquinone is used as a skin depigmenting agent, but this hydroquinone has irritation and allergic properties, and there is a problem in terms of safety in formulating it as an active ingredient in cosmetics. . Therefore, various studies have been conducted to develop cosmetics having a skin whitening effect without such disadvantages.

【0003】ところで、皮膚のシミやソバカスなどの色
素沈着はメラニン色素の過剰生成が大きな要因と考えら
れているが、このメラニン色素の生成にはたらく最も重
要な酵素が、チロシナーゼである.チロシナーゼは、メ
ラニン色素の原料であるチロシンを酸化させる酵素であ
り、メラニン色素の生成を抑えるために、この酵素の働
きを阻害もしくは抑制する研究がなされてきた.その結
果、桑白皮、せんきゅう、当帰、桂皮、夏枯草をはじめ
とする生薬抽出物(フレグランス ジャーナル1990
年 6月号 p.59)、コウジ酸及びコウジ酸誘導体
を用いた美白外用剤(特開昭53−3538号公報、特
公昭56−18569号公報、同58−22151号公
報、同60−9722号公報、同61−60801号公
報)、クエルセチンを有効成分とする化粧料(特開昭5
5−92305号公報)、クエルセチンの脂肪酸エステ
ルを有効成分とする化粧料(特開昭58−131911
号公報)、ポリフェノール骨格を有するカテキンなどを
有効成分とする化粧料(特開昭52−44375号公
報)などが開示されている。しかしながら、これらの化
粧料はいずれも、実際の使用に際しては、美白成分の安
定性がまだ不十分であったり、あるいは細胞レベルでは
効果が認められるものの、ヒトではその効果が十分に発
揮されていないなどの問題があり、必ずしも十分に満足
しうるものではない。
[0003] By the way, skin pigmentation such as spots and freckles is considered to be a major factor due to excessive production of melanin pigment. Tyrosinase is the most important enzyme that works for the production of melanin pigment. Tyrosinase is an enzyme that oxidizes tyrosine, which is a raw material of melanin pigment. Studies have been made to inhibit or suppress the action of this enzyme to suppress the production of melanin pigment. As a result, crude drug extracts such as mulberry bark, Senkyu, Toki, cinnamon bark, summer hay, etc. (Fragrance Journal 1990
June issue p. 59), an external whitening agent using kojic acid and a kojic acid derivative (JP-A-53-3538, JP-B-56-18569, JP-B-58-22151, JP-A-60-9722, and 61-). 60801), a cosmetic containing quercetin as an active ingredient (JP-A-5
No. 5-92305), cosmetics containing a fatty acid ester of quercetin as an active ingredient (JP-A-58-131911).
Japanese Patent Application Laid-Open No. 52-44375), and cosmetics containing catechin having a polyphenol skeleton as an active ingredient and the like are disclosed. However, in all of these cosmetics, in actual use, the stability of the whitening component is still insufficient, or the effect is recognized at the cellular level, but the effect is not sufficiently exhibited in humans However, it is not always satisfactory.

【0004】また甘草のフラボノイド抽出物は、油溶性
甘草エキスとも称され、グラブリジンを主成分とするも
のであり、メラニンの産生を抑制することも既に報告さ
れている(日本皮膚化学会誌102(6)679(19
92))。しかし、その美白効果にも限界があり、しか
も皮膚に対する刺激を生じることも指摘されている。
[0004] The flavonoid extract of licorice is also referred to as an oil-soluble licorice extract, which is mainly composed of glabridine and has been reported to suppress the production of melanin (Japanese Journal of Dermatology 102 (6)). ) 679 (19
92)). However, it has been pointed out that the whitening effect has a limit, and that it causes irritation to the skin.

【0005】そこで、本発明者らはこのような従来の美
白を目的とする皮膚外用剤が有する欠点を克服し、皮膚
美白効果に優れ、かつ安全性が高い上、安定性や匂いな
どについても問題のない皮膚外用剤の提供を目的とし
て、メラニン色素の生成に最も重要な役割をもつチロシ
ナーゼ活性を阻害もしくは抑制するものを鋭意探索した
結果、ポリフェノール骨格を有するもの、中でも特にエ
ラグ酸系化合物やそのアルカリ金属塩が優れていること
を見出し、先に提案した(特許登録1839986
号)。本発明者らは、さらに検討を加えた結果、特に優
れた上記エラグ酸系化合物やそのアルカリ金属塩でさ
え、化粧品や医薬部外品の基剤に配合した場合には、通
常の外用剤への配合濃度では効果が必ずしも十分ではな
いことがわかった。
Accordingly, the present inventors have overcome the drawbacks of the conventional skin whitening preparations for the purpose of whitening, are excellent in skin whitening effect, are high in safety, and have high stability and odor. For the purpose of providing a skin external preparation with no problem, as a result of earnestly searching for those which inhibit or suppress tyrosinase activity having the most important role in the production of melanin pigment, those having a polyphenol skeleton, especially ellagic acid compounds and They found that the alkali metal salt was excellent and proposed it earlier (Patent Registration 1839986).
issue). The present inventors have further studied and found that, even when the particularly excellent ellagic acid-based compound or its alkali metal salt is incorporated into a cosmetic or quasi-drug base, it can be converted into a normal external preparation. It was found that the effect was not always sufficient at the compounding concentration of.

【0006】[0006]

【発明が解決しようとする課題】本発明は、皮膚美白作
用に優れ、しかも安全性、安定性にも優れた皮膚外用組
成物を提供することを目的とする。
SUMMARY OF THE INVENTION An object of the present invention is to provide a composition for external use on the skin which is excellent in skin whitening action and also excellent in safety and stability.

【0007】[0007]

【課題を解決するための手段】上記事情に鑑み、本発明
者らは、チロシナーゼ活性を阻害もしくは抑制する物
質、その中でもポリフェノール骨格を有するもの、特に
上記エラグ酸系化合物やそのアルカリ金属塩を配合した
製剤の皮膚美白効果を向上させることを目的に検討を重
ねた結果、このような物質と、大豆、大豆粕、好ましく
はこれらを原料として発酵させたものから選ばれたもの
の抽出物および/または甘草のフラボノイド抽出物また
はその成分を併用して用いると、皮膚に対する刺激もな
く、著しく美白効果が向上することを見出し、本発明を
完成するに至った.
In view of the above circumstances, the present inventors have formulated a substance that inhibits or suppresses tyrosinase activity, in particular, a substance having a polyphenol skeleton, especially the above-mentioned ellagic acid-based compound or an alkali metal salt thereof. As a result of repeated studies for the purpose of improving the skin whitening effect of the prepared formulation, such a substance and soybean, soybean meal, preferably an extract and / or extract of those selected from those fermented using these as raw materials The present inventors have found that when a licorice flavonoid extract or a component thereof is used in combination, the whitening effect is remarkably improved without irritation to the skin, and the present invention has been completed.

【0008】即ち、本発明によれば、チロシナーゼ活性
を阻害または抑制する物質(A成分)と、大豆、大豆
粕、もしくはこれらを原料として発酵させたものから選
ばれたものの抽出物(B成分)および/または甘草のフ
ラボノイド抽出物またはその成分(C成分)とを含有す
ることを特徴とする皮膚外用組成物が提供される。
That is, according to the present invention, a substance (A component) that inhibits or suppresses tyrosinase activity and an extract (B component) of soybean, soybean meal, or a material selected from those fermented using these as a raw material And / or a flavonoid extract of licorice or a component thereof (component (C)).

【0009】[0009]

【発明の実施の形態】以下、本発明の皮膚外用組成物の
各成分について具体的に説明する。本発明の皮膚外用組
成物の有効成分のA成分であるチロシナーゼ活性を抑制
または阻害する物質は、単一の化合物、及び混合物、例
えば、天然物抽出物であり、これら物質としては、桑白
皮、せんきゅう、当帰、桂皮、夏枯草をはじめとする生
薬抽出物(フレグランス ジャーナル 1990年 6
月号 p.59)、アスコルビン酸、アルブチン、コウ
ジ酸等の化合物が挙げられ、またポリフェノール骨格を
有する物質としては、カテキン、タンニン、リグニン等
が挙げられ(日本農芸化学会誌69(9)1183(1
995))、さらに、エラグ酸系化合物及びそのアルカ
リ金属塩等が挙げられる。これらの内、ポリフェノール
骨格を有する物質や、特にエラグ酸系化合物及びそのア
ルカリ金属塩が、効果が優れており好ましい。
BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, each component of the composition for external use on skin of the present invention will be specifically described. The substance that suppresses or inhibits tyrosinase activity, which is the A component of the active ingredient of the external composition for skin of the present invention, is a single compound and a mixture, for example, a natural product extract. , Senki, Toki, cinnamon bark, summer hay and other herbal extracts (Fragrance Journal 1990 6
Monthly p. 59), compounds such as ascorbic acid, arbutin, kojic acid, and the like. Examples of the substance having a polyphenol skeleton include catechin, tannin, and lignin (Japanese Society of Agricultural Chemistry 69 (9) 1183 (1)
995)) and ellagic acid compounds and alkali metal salts thereof. Of these, substances having a polyphenol skeleton, particularly ellagic acid-based compounds and alkali metal salts thereof are preferred because of their excellent effects.

【0010】上記エラグ酸系化合物及びそのアルカリ金
属塩は、下記一般式で表されるものである。
The ellagic acid compound and the alkali metal salt thereof are represented by the following general formula.

【化1】 (式中、R1、R2、R3、R4は水素原子、炭素数1〜2
0のアルキル基、炭素数1〜20のアシル基、式−(Cm
2m−O)nH(ただし、mは2又は3、nは1以上の整
数)で示されるポリオキシアルキレン基又は式
Embedded image (In the formula, R 1 , R 2 , R 3 , and R 4 are a hydrogen atom, and have 1 to 2 carbon atoms.
0 alkyl group, acyl group having 1 to 20 carbon atoms, formula-(Cm
H 2 m-O) nH (although, m is 2 or 3, n is a polyoxyalkylene group, or the formula represented by an integer of 1 or more)

【化2】 で示される糖残基であり、それらは同一であってもよい
し、互いに異なっていてもよく、R5は水素原子、水酸
基又は炭素数1〜8のアルコキシ基を表す。)
Embedded image Which may be the same or different from each other, and R 5 represents a hydrogen atom, a hydroxyl group or an alkoxy group having 1 to 8 carbon atoms. )

【0011】該一般式(I)において、R1、R2
3、R4が炭素数1〜20のアルキル基である場合、そ
の具体例としては、メチル基、エチル基、プロピル基等
が挙げられ、特にメチル基、エチル基が好ましい。ま
た、R1、R2、R3、R4が炭素数1〜20のアシル基で
ある場合、その具体例としては、アセチル基、プロピオ
ニル基等が挙げられる。また、R1、R2、R3、R4が、
−(CmH2m−O)nHである場合、その具体例としては、
ポリオキシエチレン基、ポリオキシプロピレン基であ
り、nは1以上の整数であり、特に5〜40が好まし
い。そしてR1、R2、R3、R4は相互に同一でも、異な
っていてもよい。さらにR5が炭素数1〜8のアルコキ
シ基である場合、その具体例としては、メトキシ基、エ
トキシ基、プロポキシ基等が挙げられ、特にメトキシ基
が好ましい。更にまた、これらのエラグ酸系化合物のア
ルカリ金属塩としては、例えばナトリウム塩やカリウム
塩などが挙げられる。
In the general formula (I), R 1 , R 2 ,
When R 3 and R 4 are an alkyl group having 1 to 20 carbon atoms, specific examples thereof include a methyl group, an ethyl group, and a propyl group, and a methyl group and an ethyl group are particularly preferable. When R 1 , R 2 , R 3 and R 4 are an acyl group having 1 to 20 carbon atoms, specific examples thereof include an acetyl group and a propionyl group. Further, R 1 , R 2 , R 3 , and R 4 are
- If it is (CmH 2 m-O) nH , and specific examples thereof include
A polyoxyethylene group or a polyoxypropylene group, and n is an integer of 1 or more, and particularly preferably 5 to 40. R 1 , R 2 , R 3 , and R 4 may be the same or different from each other. Further, when R 5 is an alkoxy group having 1 to 8 carbon atoms, specific examples thereof include a methoxy group, an ethoxy group, a propoxy group and the like, and a methoxy group is particularly preferable. Furthermore, examples of the alkali metal salts of these ellagic acid compounds include sodium salts and potassium salts.

【0012】本発明のエラグ酸系化合物としては、たと
えば前記一般式(I)中のR1、R2、R3、R4及びR5
が全て水素原子であるエラグ酸や、R1、R2、R3及び
4が水素原子、メチル基又はエチル基で、R5が水素原
子、水酸基又はメトキシ基であるものが好ましく用いら
れる。また、エラグ酸のフェノール性水酸基の一部がナ
トリウム塩やカリウム塩となったものが、溶解性が良い
と云う点で好ましい。前記エラグ酸系化合物やそのアル
カリ金属塩は、皮膚外用組成物調製上、その親油性また
は親水性を調製するために、さらに、前記一般式(I)
中のR1、R2、R3及びR4のいくつかを、炭素数20ま
での長鎖アルキル基、炭素数20までの長鎖アシル基、
式(CmH2m−O−)nH(ただしmは2又は3、nは1以
上の整数)で示されるポリオキシアルキレン基及び前記
構造式(II)で表される糖残基の中から選ばれた任意の
基に置換してもよいし、R5を炭素数8までの長鎖アル
コキシに置換してもよい。
The ellagic acid compounds of the present invention include, for example, R 1 , R 2 , R 3 , R 4 and R 5 in the general formula (I).
Is preferably a ellagic acid in which R 1 , R 2 , R 3 and R 4 are a hydrogen atom, a methyl group or an ethyl group, and R 5 is a hydrogen atom, a hydroxyl group or a methoxy group. Further, ellagic acid in which a part of the phenolic hydroxyl group is converted to a sodium salt or a potassium salt is preferable in terms of good solubility. The ellagic acid-based compound and the alkali metal salt thereof are further added with the compound represented by the general formula (I) in order to adjust its lipophilicity or hydrophilicity in preparing a composition for external use on the skin.
Some of R 1 , R 2 , R 3 and R 4 in the formula are a long-chain alkyl group having up to 20 carbon atoms, a long-chain acyl group having up to 20 carbon atoms,
Selected from the sugar residue represented by the formula (CmH 2 m-O-) nH ( where m is 2 or 3, n is an integer of 1 or more) polyoxyalkylene group and the structural formula represented by (II) R 5 may be substituted with a long-chain alkoxy having up to 8 carbon atoms.

【0013】前記エラグ酸系化合物やそのアルカリ金属
塩の具体例としては、エラグ酸(一般式(1)におい
て、R1、R2、R3、R4、R5:水素原子)、3,4-ジ-o
-メチルエラグ酸(一般式(1)において、R1:メチル
基、R2:メチル基、R3:水素原子、R4:水素原子、
5:水素原子)、3,3'-ジ-o-メチルエラグ酸(一般式
(1)において、R1:水素原子、R2:メチル基、
3:水素原子、R4:メチル基、R5:水素原子)、3,
3',4-トリ-o-メチルエラグ酸(一般式(1)において、
1:メチル基、R2:メチル基、R3:水素原子、R4
メチル基、R5:水素原子)、3,3',4,4'-テトラ-o-メチ
ル-5-メトキシエラグ酸(一般式(1)において、R1
メチル基、R2メチル基:、R3:メチル基、R4:メチ
ル基、R5:メトキシ基)、3-o-エチル-4-o-メチル-5-
ヒドロキシエラグ酸(一般式(1)において、R1:メ
チル基、R2:エチル基:、R3:水素原子、R4:水素
原子、R5:水酸基)、アムリトシド(Amritoside)(一般
式(I)において、R1:前記構造式(II)、R2:水素
原子、R3:水素原子、R4:水素原子、R5:水素原子)
などや、これら化合物のアルカリ金属塩が挙げられる。
Specific examples of the ellagic acid-based compound and the alkali metal salt thereof include ellagic acid (R 1 , R 2 , R 3 , R 4 , R 5 in the general formula (1): hydrogen atom); 4-di-o
-Methylellagic acid (in the general formula (1), R 1 : methyl group, R 2 : methyl group, R 3 : hydrogen atom, R 4 : hydrogen atom,
R 5 : hydrogen atom), 3,3′-di-o-methylellagic acid (in the general formula (1), R 1 : hydrogen atom, R 2 : methyl group,
R 3 : hydrogen atom, R 4 : methyl group, R 5 : hydrogen atom), 3,
3 ′, 4-tri-o-methylellagic acid (in the general formula (1),
R 1 : methyl group, R 2 : methyl group, R 3 : hydrogen atom, R 4 :
Methyl group, R 5 : hydrogen atom, 3,3 ′, 4,4′-tetra-o-methyl-5-methoxyellagic acid (in the general formula (1), R 1 :
Methyl group, R 2 methyl group: R 3 : methyl group, R 4 : methyl group, R 5 : methoxy group), 3-o-ethyl-4-o-methyl-5-
Hydroxyellagic acid (in the general formula (1), R 1 : methyl group, R 2 : ethyl group :, R 3 : hydrogen atom, R 4 : hydrogen atom, R 5 : hydroxyl group), amritoside (Amritoside) (general formula ( In I), R 1 : the above-mentioned structural formula (II), R 2 : hydrogen atom, R 3 : hydrogen atom, R 4 : hydrogen atom, R 5 : hydrogen atom)
And alkali metal salts of these compounds.

【0014】これらのエラグ酸系化合物は、イチゴ、タ
ラ(Caesalpinia spinosa)、ユーカリ材(Eucalyptu
s)、リンゴ、毒ウツギ(コリアリア ヤポニカ)、ラ
ジアタ松、クマコケモモ、ザクロ、アンマロク、ウキュ
ウヨウ、エンフヨウ、ガイジチャ、カコウジュヨウ、カ
シ、キジュ、ケンジン、コウナカ、サンウキュウコン、
サンウキュウヨウ、シュウフウボク、センクツサイ、ソ
ウゲンロウカンソウ、ダイヒヨウソウ、ドウモウアンヨ
ウ、ハオウベン、バンセキリュウカン、バンセキリュウ
ヒ、ボウカ、モッショクシ、ヤトウセイカ、ヤトウセイ
ヒ、ユカンコン、ユカンボクヒ、ユカンヨウ、リュウガ
ソウコン、バンセキリュウヨウ、ウキュウボクコンピ、
シドコン、チンシュソウ、ゲンノショウコなどの天然物
から、以下のような方法で容易に得ることができる(特
公昭53−14605号公報参照)。
These ellagic acid compounds include strawberry, cod (Caesalpinia spinosa) and eucalyptus wood (Eucalyptu).
s), apples, poisonous azaleas (Korea yaponica), radiata pine, bear bearberry, pomegranate, anmarok, ukyuyouyou, enfuyou, kaijicha, kakojuyou, oak, kiju, kenjin, kounaka, sanukyukon,
Sankyu, Shufuboku, Senkutsusai, Sougenroukansou, Daihyousou, Domouanyou, Haouben, Banseki Ryukan, Banseki Ryuhi, Bouka, Moshoshikushi, Yatuseika, Yatou Seiyu, Yukankon, Yukanbokuyu, Yukanyukou, Yukanyukyouyu Compilation,
It can be easily obtained from natural products such as sidocon, chinsou and gennoshoko by the following method (see Japanese Patent Publication No. 53-14605).

【0015】即ち、エラグ酸系化合物を含有する上記天
然物の乾燥粉砕品を、通常の酸性亜硫酸塩法によって蒸
解後、水酸化ナトリウムや炭酸ナトリウムのアルカリ水
溶液(pH10〜13)に浸漬する。浸漬液を分取後、
浸漬液に硫酸や酢酸等の酸を加えてpHを2〜8に調整
し、エラグ酸を主成分とする沈殿物を得る。この沈殿物
を遠心分離等によって捕集し、さらに水洗することによ
り不純物を除き、純度の高いエラグ酸を得ることができ
る。なお、エラグ酸系化合物は、このように天然物中に
広く存在するものであって、安全性は極めて高いと考え
られるが、念のため安全性を確認したところ、急性毒
性、皮膚刺激性、皮膚感作性、変異原性などの点で、実
用上特に問題は認められず、安全性は高いことが確認さ
れた。
That is, a dried and pulverized product of the above natural product containing an ellagic acid compound is digested by a usual acidic sulfite method, and then immersed in an aqueous alkali solution of sodium hydroxide or sodium carbonate (pH 10 to 13). After collecting the immersion liquid,
The pH is adjusted to 2 to 8 by adding an acid such as sulfuric acid or acetic acid to the immersion liquid to obtain a precipitate mainly composed of ellagic acid. This precipitate is collected by centrifugation or the like, and further washed with water to remove impurities and obtain highly pure ellagic acid. In addition, the ellagic acid-based compound is widely present in natural products as described above, and it is considered that the safety is extremely high.However, when safety was confirmed just in case, acute toxicity, skin irritation, No practical problems were observed in terms of skin sensitization and mutagenicity, and the safety was confirmed to be high.

【0016】本発明においては、A成分であるチロシナ
ーゼ活性を抑制または阻害する化合物、その混合物、も
しくは天然物抽出物は、これらの1種又は2種以上が任
意に選ばれて用いられ、またその含有量は皮膚外用組成
物全体の0.001〜30%(%は重量%、以下同様)
が好ましく、さらに好ましくは0.05〜10%であ
る。
In the present invention, one or more of these compounds, or a mixture thereof or a natural product extract, which suppresses or inhibits the tyrosinase activity, which is the component A, may be used arbitrarily. The content is 0.001 to 30% of the whole skin external composition (% is% by weight, the same applies hereinafter).
Is more preferable, and more preferably 0.05 to 10%.

【0017】本発明の皮膚外用組成物においては、前記
A成分の美白効果を向上させるために、B成分として、
大豆、大豆粕、もしくはこれらを原料として発酵させた
もののから選ばれたものの抽出物が用いられる。原料と
なる大豆は、品種、栽培地、栽培・収穫時期、粒の外観
・性状・大きさ、蛋白・脂肪・炭水化物等の含有率を問
わない(大豆に関しては、例えば、福場博保監修 栄大
選書「大豆」女子栄養大学出版部(1984)参照)。
また、収穫後、乾燥・脱脂・脱蛋白・破砕等の前処理が
あっても構わないが、蒸煮等の処理をして発酵過程を経
たものが好ましい。
In the composition for external use on the skin of the present invention, in order to improve the whitening effect of the component A, the component B
An extract of soybean, soybean meal, or those selected from those fermented using these as a raw material is used. The soybeans used as raw materials can be of any variety, cultivation area, cultivation / harvest time, grain appearance, properties and size, protein, fat, carbohydrate, etc. (For soybeans, for example, Fukuba Hirobo Daisensho "Soybean", Women's Nutrition University Press (1984)).
After harvesting, pretreatments such as drying, degreasing, deproteinization, and crushing may be performed, but those which have been subjected to a treatment such as steaming and undergoing a fermentation process are preferred.

【0018】なお、ここでいう発酵とは、微生物もしく
はその代謝産物による作用をさす。即ち、必要に応じて
水洗、浸漬、蒸煮、破砕等の前処理をした大豆もしくは
大豆粕に、細菌(バチルス属等)、酵母(サッカロミセ
ス属等)、カビ類(アスペルギルス属等)のような微生
物を接種し、適当な温度で培養する。この際、微生物は
1種類であっても複数であっても、培養の過程で変化さ
せてもよい。また、微生物は直接接種してもコウジのよ
うな形で添加してもよく、従って、大豆の他に米、麦の
ような有機物や塩類、あるいは水を添加しても差し支え
ない。培養方法も、固体でも液体でも、静置でも攪拌・
振盪しても構わない。さらに、微生物の抽出物または代
謝産物を用いて処理してもよい。さらに、大豆を発酵さ
せた製品として、味噌、醤油、納豆、テンペ、乳腐等が
知られているが、これらを原料としても構わない。
The term "fermentation" used herein refers to the action of a microorganism or a metabolite thereof. That is, microorganisms such as bacteria (such as Bacillus), yeasts (such as Saccharomyces), and fungi (such as Aspergillus) can be added to soybeans or soybean meal that have been subjected to pretreatment such as washing, immersion, steaming, and crushing as necessary. And incubate at an appropriate temperature. At this time, the number of the microorganisms may be one or more, or may be changed during the culture. Microorganisms may be directly inoculated or added in the form of koji. Therefore, in addition to soybeans, organic substances and salts such as rice and wheat, or water may be added. The culture method can be either solid or liquid, or it can be agitated
You may shake it. Further, the treatment may be performed using an extract or metabolite of a microorganism. Further, miso, soy sauce, natto, tempe, milk tofu, etc. are known as fermented products of soybeans, but these may be used as raw materials.

【0019】抽出は、水もしくはエタノール等の有機溶
媒、あるいはこれらの混合物を用いて、攪拌・振盪もし
くは静置、あるいは循環的に行う。炭酸ガスによる超臨
界抽出も可能である。なお、抽出しないでそのまま「B
成分」として使用することも可能ではあるが、皮膚外用
組成物とするには、効果、取り扱い、外観、使用感等で
の制約が大きい。
The extraction is carried out with stirring, shaking, standing or circulating using an organic solvent such as water or ethanol, or a mixture thereof. Supercritical extraction with carbon dioxide is also possible. Note that "B"
Although it is possible to use it as a “component,” a composition for external use on the skin is largely restricted in its effects, handling, appearance, feeling of use, and the like.

【0020】なお、味噌の抽出物がメラノーマ細胞のメ
ラニン生成抑制作用を有すること(味噌の科学と技術
(2)68(1995))、その有効成分が非透析画
分にあること(日本食品科学工学会誌43(6)712
(1996))が報告されている。しかし、実用レベル
の効果を期待できるほどの美白効果は認められない。
It should be noted that the extract of miso has an effect of inhibiting melanin production of melanoma cells (Miso Science and Technology 4
3 (2) 68 (1995)) and that the active ingredient is present in the non-dialysis fraction (Japanese Society of Food Science and Technology 43 (6) 712).
(1996)). However, a whitening effect that can be expected at a practical level is not recognized.

【0021】本発明において、B成分の濃度としては、
抽出溶剤を除去した留分として、皮膚外用組成物全体の
0.001〜50%が好ましく、さらに0.01〜20
%が好ましく、特に0.1〜10%が好ましい。
In the present invention, the concentration of the component B is as follows:
As a fraction from which the extraction solvent has been removed, 0.001 to 50% of the total composition for external use on skin is preferable, and 0.01 to 20% is further preferable.
%, Particularly preferably 0.1 to 10%.

【0022】また本発明の皮膚外用組成物においては、
前記A成分の美白効果を向上させるためにC成分とし
て、甘草のフラボノイド抽出物またはその成分が用いら
れる。該甘草のフラボノイド抽出物は油溶性甘草エキス
とも称されているものであり、主成分はグラブリジンで
ある。本発明においては、C成分として抽出物を用いて
もよく、またその抽出物中に含まれるグラブリジン等の
成分そのものを用いてもよい。
In the composition for external use on the skin of the present invention,
A licorice flavonoid extract or a component thereof is used as the component C in order to improve the whitening effect of the component A. The licorice flavonoid extract is also called an oil-soluble licorice extract, and its main component is glabridine. In the present invention, an extract may be used as the C component, or a component itself such as glabridine contained in the extract may be used.

【0023】本発明において、C成分の濃度としては、
皮膚外用組成物全体の30%以下が好ましく、さらに
0.001〜20%が好ましく、特に0.01〜10%
が好ましい。
In the present invention, the concentration of the C component is
It is preferably 30% or less, more preferably 0.001 to 20%, particularly preferably 0.01 to 10% of the whole skin external composition.
Is preferred.

【0024】本発明の皮膚外用組成物においては、A成
分と、B成分および/またはC成分を併用するが、A成
分と、B成分およびC成分とを併用するのが好ましい。
また本発明の皮膚外用組成物の「A成分」と、「B成
分」および/または「C成分」の濃度の比率としては、
1:50000〜5000:1が好ましく、さらに1:
4000〜100:1が好ましく、特に1:200〜5
0:1が好ましい。
In the external composition for skin of the present invention, the component A, the component B and / or the component C are used in combination, but it is preferable to use the component A in combination with the component B and the component C.
The ratio of the concentration of “A component” and “B component” and / or “C component” of the external composition for skin of the present invention is as follows:
1: 50,000-5000: 1 is preferred, and further 1:
4000 to 100: 1 is preferable, and especially 1: 200 to 5
0: 1 is preferred.

【0025】本発明の皮膚外用組成物には、上記「A成
分」、「B成分」、「C成分」の他に、必要に応じて、
本発明の効果を損なわない範囲で、通常皮膚外用剤組成
物に用いられている種々の成分、例えば油分、水、界面
活性剤をはじめ保湿剤、アルコール、増粘剤、酸化防止
剤、金属イオン封鎖剤、pH調整剤、防腐剤、香料、色
素、紫外線吸収剤、紫外線散乱剤、ビタミン類、アミノ
酸類等を配合することができる。
[0025] In addition to the above-mentioned "Component A", "Component B" and "Component C", the composition for external use on the skin of the present invention may further comprise, if necessary,
As long as the effects of the present invention are not impaired, various components usually used in external preparations for skin, for example, oils, water, surfactants, moisturizers, alcohols, thickeners, antioxidants, metal ions Blocking agents, pH adjusters, preservatives, fragrances, pigments, ultraviolet absorbers, ultraviolet scattering agents, vitamins, amino acids, and the like can be added.

【0026】上記の皮膚外用組成物は、水溶液系、可溶
化系、乳化系、粉末分散系、水ー油2層系、水ー油ー粉
末3層系等の広い範囲の基剤であり、その用途も、クリ
ーム、乳液、化粧水、美容液、パック等の基礎化粧料、
口紅、ファンデーション等のメークアップ化粧料、ゼリ
ー剤、軟膏等の医薬品や医薬部外品等、種々の形態で幅
広く好適に使用できる。
The above-mentioned composition for external use on the skin is a wide-range base such as an aqueous solution system, a solubilizing system, an emulsifying system, a powder dispersion system, a water-oil two-layer system, a water-oil-powder three-layer system, and the like. Its uses are also basic cosmetics such as creams, milky lotions, lotions, serums, and packs,
It can be widely and suitably used in various forms such as makeup cosmetics such as lipsticks and foundations, pharmaceuticals such as jellies and ointments and quasi-drugs.

【0027】[0027]

【実施例】以下、本発明を実施例に基づいて詳細に説明
する。先ず、本発明の皮膚外用組成物の下記の各種B成
分を調製した。 [B−1成分]乾燥した「鶴の子大豆」を木槌でよく破
砕した後、エタノール100mlを添加して室温で20
時間よく攪拌した。濾過後溶媒を減圧下留去し、抽出物
2.1gを得た。 [B−2成分]市販の味噌10gに30%エタノール1
00mlを添加して室温で20時間よく攪拌した。濾過
後、溶媒を減圧下留去後、デシケータで乾燥させ、抽出
物1.5gを得た。 [B−3成分]市販の本醸造醤油100mlに酢酸エチ
ル100mlを加え、分液ロートでよく振盪した。静置
後、境界部も含めて溶媒部を回収した。再度同様に抽出
し、回収した溶媒を減圧下留去後、デシケータで乾燥さ
せ、抽出物0.4gを得た。 [B−4成分]脱脂大豆を蒸煮した後破砕し、Rhizopus
arrhizusを播種して40℃で3日間発酵させた。この
10gに30%エタノール100mlを添加して20時
間よく攪拌した。濾過後、溶媒を減圧下留去後、デシケ
ータで乾燥させ、抽出物1.4gを得た。 [C成分]甘草のフラボノイド抽出物としては、化粧品
種別配合成分規格(粧配規)に記載されているものを用
いた。
DESCRIPTION OF THE PREFERRED EMBODIMENTS Hereinafter, the present invention will be described in detail based on embodiments. First, the following various B components of the composition for external use on skin of the present invention were prepared. [Component B-1] Dried “Tsurunoko soybeans” are crushed well with a mallet, and then 100 ml of ethanol is added thereto and the mixture is added at room temperature for 20 minutes.
Stirred well for hours. After filtration, the solvent was distilled off under reduced pressure to obtain 2.1 g of an extract. [B-2 component] 30% ethanol 1 in 10 g of commercially available miso
After adding 00 ml, the mixture was stirred well at room temperature for 20 hours. After filtration, the solvent was distilled off under reduced pressure, and dried in a desiccator to obtain 1.5 g of an extract. [B-3 component] 100 ml of ethyl acetate was added to 100 ml of commercially available brewed soy sauce, and the mixture was shaken well with a separating funnel. After standing, the solvent part including the boundary part was recovered. Extraction was performed again in the same manner, and the recovered solvent was distilled off under reduced pressure, and then dried in a desiccator to obtain 0.4 g of an extract. [Ingredient B-4] Steamed defatted soybeans are crushed, and Rhizopus
arrhizus was inoculated and fermented at 40 ° C. for 3 days. 100 ml of 30% ethanol was added to the 10 g, and the mixture was stirred well for 20 hours. After filtration, the solvent was distilled off under reduced pressure, and dried in a desiccator to obtain 1.4 g of an extract. [Component C] As the flavonoid extract of licorice, those described in the standard specification of cosmetic ingredients (cosmetic regulation) were used.

【0028】実施例1 6穴のプラスチック製マイクロプレートに、B16メラ
ノーマ細胞を2.5×104個/穴播種し、5%CO2
在下、37℃で2日間培養後、培地を交換するとともに
A成分及びB成分を添加し、さらに2日間培養した。培
養終了後培地を捨て、トリプシン溶液にて細胞をプレー
トより剥離してエッペンドルフチューブに移し、遠心に
より細胞を集めた。リン酸緩衝化生理食塩水で洗浄後、
細胞の色の変化を観察した。結果を表1に示す。尚、皮
膚美白作用の評価は、細胞の色の変化を、A成分、B成
分、C成分ともに無添加の細胞の色とを比較し、次の基
準で行なった。 ±:やや退色 +:退色 ++:かなり退色 +++:著しく退色
Example 1 2.5 × 10 4 B16 melanoma cells were seeded on a 6-well plastic microplate and cultured at 37 ° C. for 2 days in the presence of 5% CO 2 , and then the medium was replaced. At the same time, the A component and the B component were added, and the mixture was further cultured for 2 days. After completion of the culture, the medium was discarded, the cells were detached from the plate with a trypsin solution, transferred to an Eppendorf tube, and collected by centrifugation. After washing with phosphate buffered saline,
The color change of the cells was observed. Table 1 shows the results. The skin whitening effect was evaluated based on the following criteria by comparing the change in the color of the cells with the color of the cells to which no A component, B component, or C component had been added. ±: slight fading +: fading ++: fairly fading +++: marked fading

【0029】[0029]

【表1】 表1から明らかなように、A成分単独に比べ、B成分お
よび/またはC成分を併用すると、B16メラノーマ細
胞の色が著しく退色することがわかる。
[Table 1] As is clear from Table 1, when the component B and / or the component C are used in combination, the color of the B16 melanoma cells is significantly faded as compared with the component A alone.

【0030】実施例2 A成分としてエラグ酸を用い、該A成分をプロピレング
リコールに1.0%溶解した美白剤(1)、前記B−1
成分をプロピレングリコール1.0%に溶解した美白剤
(2)、A成分とB−1成分をプロピレングリコールに
各々0.5%溶解した美白剤(3)、B−2成分をプロ
ピレングリコール1.0%に溶解した美白剤(4)、A
成分とB−2成分をプロピレングリコールに各々0.5
%溶解した美白剤(5)、B−4成分をプロピレングリ
コール1.0%に溶解した美白剤(6)、A成分とB−
4成分をプロピレングリコールに各々0.5%溶解した
美白剤(7)を調製し、試験に供した(各群7匹)。皮
膚美白作用の評価は下記に示す方法及び評価基準で行な
った。結果を表3に示す。なお、表3中の数字は各被験
試料と対照試料塗布のマンセル値(7匹の平均値)を示
す。
Example 2 A whitening agent (1) in which ellagic acid was used as the component A and the component A was dissolved in propylene glycol at 1.0%;
Whitening agent (2) in which components were dissolved in propylene glycol 1.0%, whitening agent (3) in which components A and B-1 were each dissolved in 0.5% in propylene glycol, and component B-2 in propylene glycol 1. Whitening agent (4) dissolved in 0%, A
Component and B-2 component in propylene glycol for 0.5
% Dissolved whitening agent (5), whitening agent (6) in which component B-4 was dissolved in propylene glycol 1.0%, component A and component B-
A whitening agent (7) in which each of the four components was dissolved in propylene glycol at a concentration of 0.5% was prepared and subjected to a test (7 animals per group). The evaluation of the skin whitening effect was performed according to the methods and evaluation criteria shown below. Table 3 shows the results. The numbers in Table 3 indicate the Munsell values (average of seven animals) of each test sample and control sample application.

【0031】[美白評価法]有色モルモットの背部体毛
をバリカン及びシェーバーで剃毛し、1日1回、計8回
の紫外線を照射することにより、各モルモットの背部に
約2.25cm2の範囲の色素沈着を2ヶ所作成した。
被験試料及び対照試料20μlを1日1回、週5回の割
合で4週間塗布し、週1回色素沈着の明度変化を標準色
票((財)日本色彩研究所、「Neutral Value Scale 3
8」)を用いて目視により評価した。そして、この明度
差を「Neutral Value Scale 38」に記載されるマンセ
ル値に換算した値から算出した。この「明度差」とは、
色素沈着の明度変化が対照(プロピレングリコールのみ
を塗布)に比較して、どの程度、紫外線照射に色素沈着
のない皮膚色に近づいているかを示すものである。評価
は表2の基準に従った。
[Whitening Evaluation Method] The back body hair of a colored guinea pig is shaved with a hair clipper and a shaver, and irradiated with ultraviolet rays once a day for a total of eight times, so that the back of each guinea pig has an area of about 2.25 cm 2 . Were made in two places.
20 μl of the test sample and the control sample were applied once a day, 5 times a week for 4 weeks, and the brightness change of the pigmentation was checked once a week by the standard color chart (Japan Color Research Institute, “Neutral Value Scale 3”).
8 "). Then, the brightness difference was calculated from a value converted into a Munsell value described in “Neutral Value Scale 38”. This "brightness difference"
It shows how much the change in lightness of the pigmentation approaches the skin color without pigmentation due to UV irradiation compared to the control (only propylene glycol was applied). The evaluation was based on the criteria in Table 2.

【0032】[0032]

【表2】 [Table 2]

【0033】[0033]

【表3】 表3から明らかなように、A成分であるエラグ酸単独よ
りも、B成分である大豆、特に大豆を発酵させたものの
抽出物とを併用すると、美白効果が著しく向上すること
がわかる。
[Table 3] As is evident from Table 3, the whitening effect is remarkably improved when the soybean as the component B, particularly an extract obtained by fermenting soybean, is used in combination with the ellagic acid as the component A alone.

【0034】実施例3 表4に示す油相成分および水相成分を別々に70℃で加
熱溶解した後、混合乳化し、冷却しながら途中で香料を
加えてさらに室温まで冷却し、乳液を調製した。
Example 3 The oil phase component and the aqueous phase component shown in Table 4 were separately heated and dissolved at 70 ° C., and then mixed and emulsified. While cooling, a fragrance was added on the way, and the mixture was further cooled to room temperature to prepare an emulsion. did.

【0035】[0035]

【表4】 [Table 4]

【0036】このようにして調製した乳液の有効性を下
記のようにして評価した。すなわち、色素斑(シミ)の
ある男女10名の色素斑部に1日2回5週間本発明品と
比較例を塗布した後、5週間後に美白効果を調べた。結
果を表5に示す。なお、美白効果の評価は下記の判定基
準により行った。 著効 :色素沈着がほとんど目立たなくなった。 有効 :色素沈着が非常に薄くなった。 やや有効:色素沈着がやや薄くなった。 無効 :変化なし
The effectiveness of the emulsion thus prepared was evaluated as follows. That is, the product of the present invention and the comparative example were applied twice a day for 5 weeks to the pigment spots of 10 men and women with pigment spots (stains), and the whitening effect was examined 5 weeks later. Table 5 shows the results. The whitening effect was evaluated according to the following criteria. Significant effect: Pigmentation became almost inconspicuous. Effective: Pigmentation was very thin. Somewhat effective: Pigmentation was slightly lighter. Invalid: No change

【0037】[0037]

【表5】 表5の結果から、本発明品であるA成分とB成分を併存
させた乳液は、各々単独の比較例に比べて、明白に美白
効果が優れていることがわかった。なお、上記乳液の5
週間の使用中及び使用後においても、皮膚の状態に異常
は認められなかった。
[Table 5] From the results in Table 5, it was found that the emulsion of the present invention, in which the component A and the component B coexist, clearly has a superior whitening effect as compared with the comparative example alone. In addition, 5 of the above emulsion
During and after weekly use, no abnormality was observed in the skin condition.

【0038】実施例4 表6に示す成分を混合して、美容液を調製した。Example 4 A serum was prepared by mixing the components shown in Table 6.

【表6】 [Table 6]

【0039】このようにして調製した本発明品である美
容液の有効性を実施例3と同様(ただし、試験期間は6
週間)にして評価した。結果を表7に示す。
The effectiveness of the thus-prepared cosmetic serum of the present invention was the same as in Example 3 (however, the test period was 6
Weeks). Table 7 shows the results.

【表7】 表7の結果から、本発明品であるA成分とB成分を併存
させた美容液は、各々単独の比較例に比べ、明らかに美
白効果に優れていることがわかった。なお、上記美容液
の6週間の使用中及び使用後においても、皮膚の状態に
異常は認められなかった。
[Table 7] From the results shown in Table 7, it was found that the serum of the present invention, in which the components A and B coexist, was clearly superior in whitening effect as compared with the comparative example alone. In addition, no abnormality was observed in the condition of the skin during and after the use of the serum for 6 weeks.

【0040】実施例5 表8に示す油相成分及び水相成分を別々に70℃で溶解
した後、溶液を攪拌しながら混合して乳化させ、室温ま
で冷却し、表8に示すクリームを調製した。
Example 5 After the oil phase component and the aqueous phase component shown in Table 8 were separately dissolved at 70 ° C., the solution was mixed and emulsified while stirring, and cooled to room temperature to prepare a cream shown in Table 8. did.

【表8】 [Table 8]

【0041】このようにして調製したクリーム剤の有効
性を下記のようにして評価した。即ち、色素斑(シミ)
のある男女10名の色素斑部を中心に、各クリーム0.
25gを1日1回6週間毎日塗布した後の美白効果を調
べた。なお、美白効果の評価は実施例3に準じた。結果
を表9に示す。
The effectiveness of the cream thus prepared was evaluated as follows. That is, pigment spots (stains)
10 creams each containing 10 pigmented spots
The whitening effect after applying 25 g once a day every day for 6 weeks was examined. The evaluation of the whitening effect was performed in the same manner as in Example 3. Table 9 shows the results.

【表9】 表9の結果から、本発明品であるA成分とB成分を併存
させたクリーム剤は、各々単独の比較例に比べ、明らか
に美白効果に優れていることがわかった。なお、上記ク
リーム剤の使用中及び使用後においても、皮膚の状態に
異常は認められなかった。
[Table 9] From the results in Table 9, it was found that the creams of the present invention, in which the component A and the component B coexist, were clearly superior in whitening effect as compared with the comparative examples alone. No abnormality was found in the condition of the skin during and after use of the cream.

【0042】[0042]

【発明の効果】本発明の皮膚外用組成物は、チロシナー
ゼ活性を阻害または抑制する物質に大豆、大豆粕もしく
はこれらを原料として発酵させたものの抽出物および/
または甘草のフラボノイド抽出物またはその成分を配合
させたことから、チロシナーゼ活性を阻害または抑制す
る物質を単独で用いたものに比べ、その皮膚美白作用が
著しく高められ、しかも皮膚カブレ等がなく皮膚に優し
い安全性に優れたものであり、かつ安定性の良好なもの
である。
EFFECTS OF THE INVENTION The composition for external use on the skin of the present invention comprises an extract of soybean, soybean meal or a fermented product thereof, which is a substance inhibiting or suppressing tyrosinase activity.
Or, because a flavonoid extract of licorice or a component thereof is blended, its skin whitening effect is significantly enhanced as compared with a substance using a substance that inhibits or suppresses tyrosinase activity alone, and furthermore, there is no skin irritation and the like. It has good gentle safety and good stability.

Claims (1)

【特許請求の範囲】[Claims] 【請求項1】 チロシナーゼ活性を阻害または抑制する
物質(A成分)と、大豆、大豆粕、もしくはこれらを原
料として発酵させたものから選ばれたものの抽出物(B
成分)および/または甘草のフラボノイド抽出物または
その成分(C成分)とを含有することを特徴とする皮膚
外用組成物。
1. A substance (A component) that inhibits or suppresses tyrosinase activity, and an extract (B) of soybean, soybean meal, or a substance selected from those fermented using these as a raw material.
And / or a flavonoid extract of licorice or a component thereof (component (C)).
JP8312965A 1996-11-08 1996-11-08 Composition for external skin use Pending JPH10139654A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP8312965A JPH10139654A (en) 1996-11-08 1996-11-08 Composition for external skin use

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP8312965A JPH10139654A (en) 1996-11-08 1996-11-08 Composition for external skin use

Publications (1)

Publication Number Publication Date
JPH10139654A true JPH10139654A (en) 1998-05-26

Family

ID=18035621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP8312965A Pending JPH10139654A (en) 1996-11-08 1996-11-08 Composition for external skin use

Country Status (1)

Country Link
JP (1) JPH10139654A (en)

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2000109417A (en) * 1998-10-05 2000-04-18 Pola Chem Ind Inc Cosmetic for improving somber color
WO2002080862A1 (en) * 2001-04-06 2002-10-17 Toyo Hakko Co., Ltd. Cosmetic materials and process for producing the same
JP2002326918A (en) * 2001-05-01 2002-11-15 Dhc Co Bleaching cosmetic
JP2004083476A (en) * 2002-08-27 2004-03-18 Horin:Kk Tyrosinase inhibitor, demelanizing agent, fibroblast reproductive factor and estrogenic substance, and skin cosmetic
JP2004137166A (en) * 2002-10-16 2004-05-13 Noevir Co Ltd Skin care preparation for external use, cell activator and antioxidant
WO2005009401A1 (en) * 2003-07-22 2005-02-03 Marta Rendon Method and topical composition for the treatment of hyperpigmented skin
JP2010150217A (en) * 2008-12-26 2010-07-08 Toyo Shinyaku Co Ltd Skin-lightening composition
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
JP2017019725A (en) * 2015-07-07 2017-01-26 公立大学法人岡山県立大学 Melanogenesis inhibitors containing urolithins

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039026B1 (en) * 1997-07-28 2011-10-18 Johnson & Johnson Consumer Companies, Inc Methods for treating skin pigmentation
US8106094B2 (en) 1998-07-06 2012-01-31 Johnson & Johnson Consumer Companies, Inc. Compositions and methods for treating skin conditions
US8093293B2 (en) 1998-07-06 2012-01-10 Johnson & Johnson Consumer Companies, Inc. Methods for treating skin conditions
JP2000109417A (en) * 1998-10-05 2000-04-18 Pola Chem Ind Inc Cosmetic for improving somber color
US7985404B1 (en) 1999-07-27 2011-07-26 Johnson & Johnson Consumer Companies, Inc. Reducing hair growth, hair follicle and hair shaft size and hair pigmentation
US8431550B2 (en) 2000-10-27 2013-04-30 Johnson & Johnson Consumer Companies, Inc. Topical anti-cancer compositions and methods of use thereof
US7897144B2 (en) 2001-02-28 2011-03-01 Johnson & Johnson Comsumer Companies, Inc. Compositions containing legume products
WO2002080862A1 (en) * 2001-04-06 2002-10-17 Toyo Hakko Co., Ltd. Cosmetic materials and process for producing the same
JPWO2002080862A1 (en) * 2001-04-06 2004-07-29 株式会社東洋発酵 Beauty cosmetic material and its manufacturing method
JP2002326918A (en) * 2001-05-01 2002-11-15 Dhc Co Bleaching cosmetic
JP2004083476A (en) * 2002-08-27 2004-03-18 Horin:Kk Tyrosinase inhibitor, demelanizing agent, fibroblast reproductive factor and estrogenic substance, and skin cosmetic
JP2004137166A (en) * 2002-10-16 2004-05-13 Noevir Co Ltd Skin care preparation for external use, cell activator and antioxidant
WO2005009401A1 (en) * 2003-07-22 2005-02-03 Marta Rendon Method and topical composition for the treatment of hyperpigmented skin
JP2010150217A (en) * 2008-12-26 2010-07-08 Toyo Shinyaku Co Ltd Skin-lightening composition
JP2017019725A (en) * 2015-07-07 2017-01-26 公立大学法人岡山県立大学 Melanogenesis inhibitors containing urolithins

Similar Documents

Publication Publication Date Title
JP4025546B2 (en) Skin beautifying agent, skin anti-aging agent, whitening agent and skin external preparation
CN101578092B (en) Cosmetic composition for skin whitening comprising arctiin, arctigenin or the mixture thereof as active ingredient
US20070274937A1 (en) Use of a Cruciferous Protein Hydrolysate as a Depigmentation Agent or For a Cosmetic and/or Pharmaceutical Composition
CN101815498B (en) Use of lignan compound for anti-wrinkle treatment
KR20110108687A (en) Skin whitening agent containing extracts of natural materials and composition of cosmetic
JPH10139654A (en) Composition for external skin use
KR100500641B1 (en) Composition for preventing falling out of the hair or promoting growth of the hair containing isoflavone aglycon genistein
KR101336804B1 (en) Fermented ear shell using mushroom, manufacturing method thereof and cosmetic composition comprising the same
JP2000044485A (en) Active oxygen species scavenger and skin cosmetic
US8431550B2 (en) Topical anti-cancer compositions and methods of use thereof
WO2020054204A1 (en) Antioxidant
JP2007210976A (en) Tyrosinase activity inhibitor and bleaching cosmetic containing the same
KR100723844B1 (en) Health care and skin care bath and beauty material using fermented soybean extract
KR20080049332A (en) Skin-whitening extract from oviductus ranae
KR102154927B1 (en) A cosmetic composition for anti-aging, anti-oxidant, skin regeneration comprising chlorogenic acid, ferulic acid, resveratrol, and Streptococcus thermophilus fermented extract
CN101360478B (en) Cosmetic composition containing extracts of pinus koraiensis as active ingredient
KR102016062B1 (en) Callus extracts from Citrus junos Siebold ex Tanaka and Pyrus pyrifolia Nakai with Whitening and Anti-wrinkle effect
CN109464372A (en) A kind of external-use skin care combination and preparation method with three-dimensional white-skinned face function
KR102541480B1 (en) Method for preparing red-ginseng vinegar and composition comprising thereof
KR101854766B1 (en) Skin whitening complex containing trihydroxyisoflavone and glycyrrhiza uralensis extracts
KR20190081627A (en) Cosmetic composition for whitening and anti-wrinkle containing Batillus cornutus derived peptide powder
JP2001181197A (en) Olive extract
KR20180094641A (en) Method for preparing extract of fermented silkworm cocoon and a cosmetic composition containing fermented extract of silkworm cocoon as an active ingredients
JP3885243B2 (en) Skin cosmetics
JPH11193243A (en) Skin preparation for external use